July 08, 2016
A New Jersey federal judge on Thursday pressed the pause button on a pair of proposed shareholder class actions against Celator over its planned $1.5 billion sale to Jazz Pharmaceuticals, after the sides reached a tentative settlement agreement.
June 28, 2016
A Celator investor asked a New Jersey federal court Monday to halt the oncology biotech's planned $1.5 billion sale to Jazz Pharmaceuticals, contending the too-low deal is the result of a flawed and "coercive" sales process that benefits company insiders at the expense of shareholders.